SymBio Pharmaceuticals Limited
Corporate Governance
Last updated: June 16, 2016
SymBio Pharmaceuticals Limited
Representative DirectorPresident and Chief Executive OfficerFuminori Yoshida
For inquiries phone: 03-5472-1125(Securities Code: 4582)
URL: http://www.symbiopharma.com/

The corporate governance policies of SymBio Pharmaceuticals Limited (“SymBio” or “We”) aredescribed below.

I. Basic Policy on Corporate Governance, Capital Structure, Corporate Profile and Other Basic
Information
1. Basic Policy
SymBio was founded on the basis of the aspirations of "co-creation and symbiosis". It isSymBio’s philosophy that a mutually supportive relationship exists between physicians,scientists, regulators, and investors, with patients located at the center, and We aim for full
realization of this principle as a mission. With the recognition that the pursuit of this principle
leads to the improvement of corporate value, We strengthen our corporate governance and try
to improve management efficiency and infusion of business ethics, to secure soundmanagement.

【Reasons for not implementing each principle of the Corporate Governance Code】
We have implemented all the principles of the Tokyo Stock Exchange’s (“Exchange”) Corporate
Governance Code (“Code”).

【Disclosure based on corresponding principles in the Code】
In compliance with the five basic principles of the Code, the contents of our initiatives will be
disclosed regarding the supplementary principles described below:

Full Disclosure: Supplementary Principle 3-1②
To date, the ratio of non-Japanese to Japanese SymBio shareholders has never been high.
SymBio recognizes that this has a major influence on the approval or lack thereof for agendas
since non-Japanese shareholders are entitled to use their voting rights at general meetings ofshareholders. In this regard, SymBio translates our Notice of Convocation of the Ordinary
General Meeting of Shareholders into English and places it on our website and the Exchange’swebsite to facilitate the exercise of voting rights. In addition, since actively implementing
investor relations is positioned as an important management policy, SymBio further discloses
the English version of SymBio’s press release information through our website in addition tothe Japanese version, regardless of timely disclosure obligations.

External Auditors: Supplementary Principle 3-2①SymBio’s Audit & Supervisory Board has devised appropriate standards for the selection ofexternal accounting auditor candidates, and for evaluating the independence and expertise of
our external accounting auditors in reference to the Practical Guidelines of the Japan
Corporate Auditors Association. In addition, based on those standards, the Audit &Supervisory Board carries out an evaluation of our external accounting auditors, and verifies
whether they possess the necessary independence and expertise to fulfill their responsibilities.

Effective Use of Independent Directors: Supplementary Principle 4-8①
In addition to SymBio’s Board of Directors’ Meetings, each year we hold 4 other meetings
aimed at information exchange and sharing awareness with outside directors (4 non-Japanesemale members and 1 Japanese female member).

Preconditions for Board and Audit & Supervisory Board Effectiveness:
Supplementary
Principle 4-11③
SymBio is pushing forward with the annual “analysis and evaluation” of the effectiveness ofthe Board of Directors, in conjunction with directors’ “self-evaluations”. In addition, We willconsider disclosure of the results of the foregoing.